Funding Climate– tag –
-
Bonus Track-Special: Redesigning M&A & Partnerships — From Overlap Removal to “Rights Architecture”
Category: Pharma & Biotech NEWS | Special Feature A Key Takeaways PMI defines value: 80% of deal value crystallizes within 90–180 days post-close through speed and transparency; eliminate overlaps with KPI governance. Rights redesign... -
Series “Reading 2025 Layoffs” — Final: Practical Playbook: Checklists and Capital Strategy for Founders & Investors (Part 5)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 5 (Final) Key Takeaways Event-synced planning: script data (BM → topline) and financing (FPO/debt/partnerships) to minimize dilution. Shortest path to POC: focus ... -
Series “Reading 2025 Layoffs”: The Funding Climate: How Selectivity Works Across VC, Public, Debt, and M&A (Part 4)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 4 Key Takeaways Capital concentrates near POC: late-stage/near-commercial assets attract flows; discovery–preclinical is tightly screened; non-dilutive capital br... -
Series “Reading 2025 Layoffs”: Reshaping by Disease Areas: From Oncology to Neuroscience (Part 2)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 2 Key Takeaways Oncology leads the reallocation: Cell therapies and solid tumors force a focus on indication picking, manufacturability, and reimbursement realism...
1